StartUPDATES is a member feature of MedCitizens, a community of MedCity News startups. Submit here and join.
NeuroFlow and Jefferson Health collaborated to develop a version of NeuroFlow’s behavioral health monitoring platform for 20 different departments at the health system, starting with OBGYN for postpartum depression.
The digital platform facilitates healthcare management for clinicians and patients in between traditional office-based visits. Clinicians can assign surveys to patients, set reminders, encourage mindfulness and meditation sessions. Data is collected and sent to the care team to review for outlier behavior or struggles with treatment. The mobile-friendly platform helps patients communicate progress and understand that treatment and mental well-being is a process that requires their engagement for success. Healthcare teams can intervene or adjust a patient’s treatment based on data received. The tool is similar to what NeuroFlow developed with IntegrateHealth.
“It’s critical to integrate mental with physical wellness, and I’m proud that Jefferson will be the first academic health center to collaborate with NeuroFlow,” said Dr. Stephen Klasko, president of Thomas Jefferson University and CEO of Jefferson Health. “Together, we can reinforce the vital link between physical and mental health and ensure patients are more engaged. It will deliver better outcomes and reduce the administrative burden placed on our providers.”
Solve.Care, a care coordination, administration and medical payment startup enlisting blockchain, has inked a deal with Uber Health. Users of Solve.Care’s Care.Wallet healthcare application will be able to schedule Uber Health rides to medical appointments and pay for the rides through the platform. Click here to read more.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
GNS Healthcare has raised a $23 million Series D funding round. The company, which uses machine learning to optimize drug development and patient care management programs, led by Cigna Ventures. GNS intends to use the funding to help clients such as Cigna to provide more personalized care delivery. Cigna Ventures led the round but some other investors included Amgen Ventures, Celgene, Echo Health Ventures, and Alexandria Venture Investments. Click here to read more.
Image: Getty Images
